Avoiding Aluminum in an Age That Did Not Evolve with It

HHS is committed to asking tough questions too few want answers to. ACIP moves will need backing.Please share to social media and tag your U.S. Senator asking them to have their staff learn the facts.

Aluminum is an Unwanted Burden

Humans did not evolve with bioavailable aluminum. In fact, for most of evolutionary history, aluminum was locked in silicate rocks and clays, largely insoluble and biologically inert. But industrial processes—from water treatment to food additives to pharmaceutical formulation—have forced aluminum into soluble, absorbable forms. The result is unprecedented and chronic exposure across all routes: ingestion, inhalation, dermal absorption, and injection.

At high doses, aluminum is undeniably neurotoxic. Dialysis patients exposed to high-aluminum dialysate developed a fatal encephalopathy, osteomalacia, and microcytic anemia until aluminum removal reversed the epidemic [Parkinson et al., 1981]. But what happens at low doses—those received every day, by nearly everyone—is less obvious. Evidence of low-dose toxicity (hormesis) exists, and the body seems to accumulate via immunosequestration large amounts of aluminum in ways that are harmful to tissue over time. Regulators have leaned on assumptions about poor absorption and rapid clearance. Yet low-dose kinetics tell a different story: aluminum is slowly absorbed, but the portion that is absorbed is poorly excreted, and accumulates in vulnerable tissues over time.

This article maps the evidence of sources and the rational basis of concerns over policies that ignore the evidence. It examines what we know about aluminum absorption, tissue distribution, and retention. It quantifies the actual exposure from diet, water, pharmaceuticals, and vaccines. It presents the emerging evidence of harm in the brain and other organs and offers practical guidance on how to reduce exposure and enhance clearance. From all sources.

2. Aluminum in the Body: Low-Dose Kinetics and an Unevolved Metal

Modern toxicokinetics show that aluminum is absorbed in humans at low but non-trivial fractions—especially at the trace levels most common in food and water. Yokel and McNamara estimated oral absorption from drinking water to be approximately 0.3%, a figure supported by multiple tracer studies using ^26Al isotopes [Yokel & McNamara, 2001]. For aluminum salts commonly used in food, absorption in rats ranged from 0.05–0.21% [Priest et al., 2021].

Importantly, low doses are often absorbed at higher relative rates than high doses. In a human balance study, men who consumed 5 mg/day aluminum had absorption fractions between 0.28% and 0.76%, while those consuming 125 mg/day had lower absorption fractions (~0.09%) [Greger & Baier, 1983]. This non-linear dose-response means that chronic low exposures may matter more than high-dose studies suggest.

Once absorbed, about 50% of aluminum deposits in bone, where it replaces calcium in hydroxyapatite and clears with a half-life measured in years [ATSDR, 2008]. Smaller fractions circulate as aluminum–citrate or aluminum–transferrin complexes and cross into the brain. There, aluminum accumulates preferentially in the hippocampus and cortex, with limited ability to be cleared [Yokel et al., 2002].

Dermal absorption is lower. Flarend et al. (2001) estimated systemic uptake from antiperspirants at ~0.012% of applied dose. But even here, low-dose studies used short durations and few participants. Parenteral aluminum (via injection or infusion) is nearly 100% systemically available, with slow tissue dissolution and depot effects [Mitkus et al., 2011].

In short: absorption is low but persistent, clearance is slow, and dose builds over time. Every day of exposure adds to a body burden that cannot be easily eliminated.

3. Chronic Low-Level Exposure: Brain Deposition and Mechanistic Plausibility

We already know that high-dose aluminum can be devastating. But the central question in public health is what happens at low, persistent doses—across decades, across systems, and across generations.

Brain Tissue Evidence: Autopsy and Histologic Findings

In a 2018 study, Mold et al. analyzed 10 brains from individuals with autism and found aluminum concentrations as high as 22.1 µg/g dry weight—levels similar to or exceeding those in Alzheimer’s disease [Mold et al., 2018]. Aluminum localized in microglia, perivascular cells, and non-neuronal compartments.

In Alzheimer’s disease, Perl and Brody (1980) found aluminum selectively in neurofibrillary tangle-bearing hippocampal neurons. Follow-ups confirmed co-localization with iron and neuropathology [Good et al., 1992; Walton, 2006]. Exley et al. proposed that brain aluminum levels above 3–4 µg/g dry weight likely indicate pathology [Exley, 2004].

Mechanisms: Iron Dysregulation, ER Stress, Synaptic Distortion

Mechanistically, aluminum disrupts iron metabolism by altering transferrin receptor function and ferritin expression, leading to oxidative stress and ROS production [Skalny et al., 2021]. It induces ER stress and activates the unfolded protein response (UPR), interfering with protein folding due to its high affinity for phosphate and carboxylate groups.

Chronic exposure of rat hippocampal neurons to aluminum reduces NMDA receptor subunits (NR1 and NR2A/B) by up to 75%, without inducing apoptosis—suggesting disruption of synaptic development [Zhou et al., 2008].

Together, these data show that aluminum accumulates in the brain, co-localizes with pathology, and has multiple pathways to impair neuronal health.

4. Epidemiology: Drinking Water, Silica, and Dementia

The PAQUID cohort in France (~3,700 elderly subjects) found that aluminum in drinking water >0.1 mg/L was associated with increased Alzheimer’s risk, while higher silica (>11.25 mg/L) reduced risk [Rondeau et al., 2009]. This echoed earlier findings linking aluminum with dementia.

Other cohorts, like the Canadian Study of Health and Aging, found no clear overall association, but suggested a possible link in APOE-ε4 carriers [Van Dyke et al., 2021]. Reviews by Nie et al. (2024) found 12 of 20 studies showing positive associations, with others null or inconclusive.

The strongest pattern is that silica appears protective. Jugdaohsingh et al. (2000) showed that oligomeric silica reduces aluminum bioavailability by ~70% in human volunteers.

5. Cumulative Exposure Cartography: Sources, Speciation, and Uptake

Aluminum from any source can be expected to contribute to total risk of poor health due to aluminum exposure; cumulative exposure = cumulative risk. Blame-shifting will not solve the total exposure problem.

Food

Infant formula is a quiet but significant aluminum source in early life, especially for babies who are formula-dependent or on specialized products. Multiple surveys of commercial formulas have shown that ready-to-feed cow’s-milk formulas often fall in the ~150–400 µg/L range, while soy-based formulas are higher, commonly around 0.5–1.0 mg/L aluminum when prepared as directed. Redgrove and colleagues extended this work to prescription formulas used for preterm infants, poor weight gain, allergies, and renal disease. In their 2019 study of 24 prescription products, aluminum in ready-to-drink formulas ranged from about 50 to nearly 2,000 µg/L, with the highest levels in weight-gain supplements, and powdered specialty formulas contained roughly 0.27–3.27 µg/g. At typical intake volumes, that translates into daily aluminum doses in the hundreds of micrograms—and in some preterm or failure-to-thrive infants, over 600 µg/day, every day, from birth.

Dórea’s review of early-life metal exposure makes the obvious but usually ignored point: formula is not just “food,” it is often an infant’s entire diet, so any contamination acts as a continuous exposure rather than an occasional spike. On a per-kilogram basis, a 3 kg formula-fed newborn receiving several hundred micrograms of aluminum per day from a high-Al formula is in the same dosage ballpark as adults in classic parenteral toxicity studies once fractional absorption (≈0.1–0.3%) and immature renal function are taken into account. Combined with injected aluminum from vaccines, the formula contribution helps explain why IPAK’s modeled body burdens in early infancy are dominated by routes that simply did not exist in our evolutionary past. The Redgrove data also expose a policy lever: some of the most expensive specialist formulas in their series had the lowest aluminum levels ever measured in that lab, proving that high contamination is not inevitable but the result of choices in ingredients, processing, and packaging that manufacturers could change tomorrow.

EFSA estimates daily aluminum intake from food at 2–15 mg/day [EFSA, 2008]. Saiyed and Yokel (2005) showed that:

• Baking powder can contain up to 27,000 mg/kg aluminum

• Pancake/waffle mixes can deliver 180 mg/serving

• Processed cheese (frozen pizza) can deliver 14 mg/serving

• Non-dairy creamers: 1.5 mg/serving

Single meals can eclipse multiple days’ worth of total aluminum intake. Absorption fractions of 0.1–0.4% still yield meaningful internal doses.

One striking lesson from the food tables is that aluminum exposure is not evenly distributed across the diet; it clusters in very specific industrial and traditional products. Raw foods like spinach (~45 mg/kg) and rhubarb (~170 mg/kg) carry modest aluminum loads compared with their processed descendants, while tea leaves can reach ~260 mg/kg by the third infusion. But once food technologists and processors begin using aluminum-based additives, the numbers become bizarre. Processed cheese can hit ~650 mg/kg, non‑dairy creamers ~600 mg/kg, and common baked items made with aluminum‑based leavening—breads, buns, cakes, muffins, waffles—range from roughly 100 to 320 mg/kg, with cornbread around 450 mg/kg. The outliers are even more revealing: baking powder at ~16,000 mg/kg and canned or processed jellyfish around 1,200 mg/kg, where alum or related salts are used as firming agents.

From a toxicology perspective, those tables show that aluminum in food is less about “what grows in the ground” and more about what is done to it. Aluminum phosphates and sulfates are added to baking mixes for texture and rise; sodium aluminosilicate is added to salt and dry mixes as an anti‑caking agent; alum is used in pickling and in certain regional specialties (including processed jellyfish) to stiffen tissues and preserve a particular “bite.” Each of these uses is technically justified at the level of product performance, but they create dishes where a single serving can deliver tens to hundreds of milligrams of aluminum—orders of magnitude above the background levels in the base ingredients. When you then fold in the EFSA estimate that average adult diets already reach 2–15 mg/day, and that children at the high end of intake exceed the tolerable weekly intake on diet alone, these oddly high values stop being curiosities and start looking like the true leverage points for exposure reduction. Eliminating a handful of aluminum‑rich products—baking powders, processed cheeses, certain pickled or canned foods, aluminum‑leavened mixes—likely does more to reduce real‑world aluminum burden than agonizing over trace levels in soil or tap water.

Cookware and Foil

Hiller et al. (2023) found that using aluminum foil in food preparation raised urinary aluminum by ~8%, which reversed after stopping. Even short-term exposures from cookware are measurable.

Water

Most municipal water contains <0.1 mg/L aluminum. Yet absorption from water (~0.3%) is often higher than from food. Acidic pH and low silica increase absorption. Co-ingested citrate enhances bioavailability.

Pharmaceuticals

Antacids and buffered aspirin can contain 500–5,000 mg aluminum per day. Even with low absorption (~0.01%), these contribute significantly to body burden—especially in individuals with impaired renal function.

Vaccines

Regulators still lean heavily on a single modeling paper by Mitkus and colleagues, which claimed that aluminum exposures from the infant vaccine schedule remain below toxic thresholds when compared with a “minimal risk level” derived from dietary studies in adult mice and scaled to humans. However, this model equated orally ingested aluminum citrate in adult animals with intramuscularly injected aluminum oxyhydroxide in human neonates, and further assumed rapid systemic clearance with negligible tissue retention. The resulting model overlooked known differences in pharmacokinetics by route of administration and developmental stage, and substantially underestimated body burden.

Lyons-Weiler and Ricketson reanalyzed the regulatory basis for aluminum safety, showing that a provisional weekly intake value of 1,000 µg/kg had been erroneously reused as a daily value, inflating the implied safety margin by 7-fold. They recalculated pediatric minimum risk levels (MRLs) using corrected scaling from mouse data and standard safety factors, resulting in much lower MRLs for neonates (10–16 µg/kg/day) and infants at 2 years (58 µg/kg/day). They then used Clark’s Rule to translate the FDA’s 850 µg per-dose ceiling into pediatric dose limits (PDLs) by weight. The result: typical CDC schedule doses far exceed these limits, with a single HepB shot in a 3.3 kg newborn yielding 76 µg/kg/day, and 125–150 µg/kg/day in a 2 kg NICU infant.

McFarland et al. extended this to full-body retention using human tracer data (Priest et al.), modeling cumulative exposure across three schedules: the standard CDC, a low-aluminum variant, and the Vaccine Friendly Plan (VFP). Under conservative retention assumptions, the CDC schedule exceeded the safe PDL on ~70% of days in the first 7 months and ~24% of days over two years. %AlumTox (percent of days above toxic threshold) fell to 26% and 8% for the low-aluminum and VFP schedules, respectively. When incorporating reduced clearance due to genetics or immature renal function, %AlumTox for the CDC schedule increased dramatically: >80% for low-birthweight infants.

In a follow-up study, Lyons-Weiler, McFarland, and La Joie corrected the PDL curve for glomerular filtration rate (GFR) development from birth to two years. Accounting for immature kidney function, they found the CDC schedule kept median-weight infants above the toxic threshold for essentially 100% of days during the first year of life and 52% over the first 800 days. A six-month delayed start reduced that to 21%, but the best-performing schedule—using low-aluminum vaccines and spacing out doses—reduced toxicity to 2–7% of days, depending on weight.

This three-paper series demolishes the core assumptions behind Mitkus et al.’s comfort model. Once dose scaling, retention, and pediatric physiology are correctly incorporated, the conclusion is unavoidable: the standard infant vaccine schedule routinely drives aluminum body burden above toxic thresholds for months at a time, especially in low-weight infants. Regulatory reliance on adult mouse oral exposure data and misapplied safety factors has permitted a chronic overexposure scenario that would not be allowed in any other therapeutic context.

Dermal Exposure

Flarend et al. (2001) estimated dermal absorption from antiperspirants at 0.012%. Systemic contribution is small but not zero. For those with high total body burden or renal compromise, even small routes add up.

6. Trait Matrix: Who Is Most at Risk?

Risk is not equal across populations. Infants have low body mass, and, like the the elderly absorb more, retain more, and have fewer reserves. Autoimmunity and toxicant synergy further compound effects.

7. Mitigation and Clearance

Avoidance

• Choose aluminum-free baking powder and processed foods

• Avoid antiperspirants with aluminum salts

• Use stainless steel or cast iron cookware

• Avoid aluminum-containing antacids and buffered aspirin when alternatives exist

• Filter drinking water; seek high-silica mineral water (e.g., Volvic, Fiji)

Chelation and Silica

Davenward et al. (2013) found that silicon-rich water (30 mg/L) increased urinary aluminum excretion in Alzheimer’s patients. Jones et al. (2017) showed similar results in multiple sclerosis.

Jugdaohsingh et al. (2000) demonstrated that oligomeric silica reduces aluminum absorption by ~70%. Buffoli et al. (2013) found that silica also improves vascular function and endothelial NO synthase expression in mice.

Herbal supports include: - Cilantro (mobilizer) - Chlorella/spirulina (binders) - Vitamin C (supports renal clearance) - Probiotics (gut barrier integrity)

Chelation protocols using DMSA, DMPS, or lipoic acid should be medically supervised.

8. Regulatory Models vs. Physical Reality

Regulatory bodies like EFSA and ATSDR treat aluminum exposure as safe because it is “poorly absorbed” and because evidence linking it to Alzheimer’s is not conclusive. But those claims ignore:

• Trace-level absorption with long tissue retention

• Iron dysregulation and UPR activation in glia and neurons

• Brain deposition in autism and AD

• Neurotoxicity in dialysis patients

Models used by Mitkus et al. assume uniform dissolution, rapid clearance, and adult kinetic constants. Yet animal studies and chelation trials contradict those assumptions. There is little empirical measurement of aluminum deposition in tissues post-vaccine or post-injection.

Risk is not linear, not uniform, and not zero.

9. Conclusion: Aluminum is a Design Flaw, Not a Mystery

Aluminum exposure is not a mystery. It is a predictable consequence of industrial convenience overtaking biological design. Chronic exposure builds over time. Accumulation happens in bone, brain, and possibly other organs. And clearance is glacial.

Avoidance is not alarmism. It is rational harm reduction. Choose silica-rich water. Avoid aluminum additives. Limit injected and pharmaceutical sources. Push for clinical trials that test removal protocols.

This is not about panic; it’s about policy impacts on the long view of human health.

References

Parkinson IS, Ward MK, Kerr DN. Dialysis encephalopathy, bone disease, and anaemia: the aluminium intoxication syndrome in renal failure. Lancet. 1981;2(8243):841–845. https://doi.org/10.1016/S0140-6736(81)90921-5

Greger JL, Baier MJ. Excretion and retention of low or moderate levels of aluminum by human subjects. Food Chem Toxicol. 1983;21(4):473–477. https://doi.org/10.1016/0278-6915(83)90055-0

Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol. 2001;88(4):159–167. https://doi.org/10.1034/j.1600-0773.2001.880401.x

Yokel RA, Allen DD, Ackley DC. The distribution of aluminum into and out of the brain. J Inorg Biochem. 2002;88(2):165–169. https://doi.org/10.1016/S0162-0134(01)00361-1

Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann Neurol. 1992;31(3):286–292. https://doi.org/10.1002/ana.410310309

Walton JR. Evidence for participation of aluminum in neurofibrillary tangle formation and growth in Alzheimer’s disease. J Alzheimers Dis. 2006;9(3):287–293. https://doi.org/10.3233/JAD-2006-9305

Exley C. The pro-oxidant activity of aluminum. Free Radic Biol Med. 2004;36(3):380–387. https://doi.org/10.1016/j.freeradbiomed.2003.11.003

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Aluminum. U.S. Department of Health and Human Services; 2008. https://www.atsdr.cdc.gov/toxprofiles/tp22.pdf

European Food Safety Authority (EFSA). Safety of aluminium from dietary intake. EFSA J. 2008;6(7):754. https://doi.org/10.2903/j.efsa.2008.754

Zhou Y, Wang H, Shi Y, et al. Developmental exposure to aluminum induces a dose-dependent decrease in the expression of NMDA receptor subunits in the rat hippocampus. J Neurosci Res. 2008;86(9):2084–2090. https://doi.org/10.1002/jnr.21664

Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169(4):489–496. https://doi.org/10.1093/aje/kwn348

Redgrove K, Alfrey S, Jeffery H, Hatch A, Morley R. Aluminum content of milk formulas. J Pediatr Gastroenterol Nutr. 2019;68(5):686–690. doi:10.1097/MPG.0000000000002266

Dórea JG. Exposure to environmental mercury and lead in early life: developmental vulnerability, neurotoxicity, and epigenetic mechanisms. Environ Res. 2021;197:111192. doi:10.1016/j.envres.2021.111192

Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011;29(51):9538–9543. https://doi.org/10.1016/j.vaccine.2011.09.124

Mold M, Umar D, King A, Exley C. Aluminium in brain tissue in autism. J Trace Elem Med Biol. 2018;46:76–82. https://doi.org/10.1016/j.jtemb.2017.11.012

Lyons-Weiler J, Ricketson R. Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum. J Trace Elem Med Biol. 2018;48:67–73. https://doi.org/10.1016/j.jtemb.2018.02.025

McFarland G, La Joie E, Thomas P, Lyons-Weiler J. Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation. J Trace Elem Med Biol. 2020;58:126444. https://doi.org/10.1016/j.jtemb.2019.126444

Lyons-Weiler J, McFarland G, La Joie E. Impact of catch-up vaccination on aluminum exposure due to new laws and post social distancing. J Trace Elem Med Biol. 2020;62:126649. https://doi.org/10.1016/j.jtemb.2020.126649

Priest ND, Talbot RJ, Newton D, Day JP, King SJ. The bioavailability and retention of aluminum in rats following oral exposure to aluminum compounds. Food Chem Toxicol. 2021;152:112220. https://doi.org/10.1016/j.fct.2021.112220

Skalny AV, Aschner M, Tinkov AA, et al. Neurotoxicity of aluminum: systemic review of existing data. Metallomics. 2021;13(2):190–217. https://doi.org/10.1093/mtomcs/mfab006

Van Dyke MI, Charette M, Orsat V, Champagne CP. Epidemiologic evidence of aluminum exposure and Alzheimer’s disease: a systematic review. Neurotoxicology. 2021;84:13–29. https://doi.org/10.1016/j.neuro.2020.12.007

Davenward S, Bentham P, Wright J, et al. Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease. J Alzheimers Dis. 2013;33(2):423–430. https://doi.org/10.3233/JAD-2012-121231

Jones K, Davenward S, Wright J, Crome P, Exley C. Urinary excretion of aluminum and silicon in secondary progressive multiple sclerosis. EBioMedicine. 2017;26:60–67. https://doi.org/10.1016/j.ebiom.2017.10.028

Buffoli B, Foglio E, Borsani E, Exley C, Rezzani R, Rodella LF. Silicic acid in drinking water prevents age-related alterations in the endothelium-dependent vascular relaxation. Acta Histochem. 2013;115(5):418–424. https://doi.org/10.1016/j.acthis.2012.10.002

Saiyed SM, Yokel RA. Aluminium content of some foods and food products in the USA, with aluminium food additives. Food Addit Contam. 2005;22(3):234–244. https://doi.org/10.1080/02652030500073584

Hiller J, Degen GH, Hengstler JG, et al. Effect of an aluminum foil-processed diet on internal human aluminum burden: A randomized controlled trial. Environ Int. 2023;177:108000. https://doi.org/10.1016/j.envint.2023.108000

Jugdaohsingh R, Cremin S, Powell JJ, et al. Oligomeric but not monomeric silica prevents aluminum absorption in humans. Am J Clin Nutr. 2000;71(4):944–949. https://doi.org/10.1093/ajcn/71.4.944